Try our mobile app

Switch to company model in "Rising Stars" logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Veracyte, Inc. develops molecular tests for oncology. The Company offers molecular cytology and tests for the diagnostic accuracy of cytology samples. Veracyte provides its products and services to healthcare and molecular diagnostic companies in the United States.
Website: veracyte.com


  • Good financial results growth rate 109.2% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (10.2%)
  • Dividend yield for the last twelve months 0.0%
  • Free cash flow yield 3.5% (LTM)
  • Share price is 153.4% higher than minimum and 3.2% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (43.7x vs 30.0x)
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $4.7 mln (-0.152% of cap.)

Key Financials (Download financials)

Ticker: VCYT
Share price, USD:  (-0.8%)47.8
year average price 36.85  


year start price 27.29 2025-06-04

min close price 23.03 2025-07-21

max close price 49.38 2025-11-25

current price 47.80 2026-06-03
Common stocks: 79 178 087

Dividend Yield:  0.0%
FCF Yield LTM: 3.5%
EV / LTM EBITDA: 43.7x
EV / EBITDA annualized: 20.3x
Last revenue growth (y/y):  +18.5%
Last growth of EBITDA (y/y):  +200.0%
Historical revenue growth:  +20.3%
Historical growth of EBITDA:  0.0%
EV / Sales: 6.6x
Margin (EBITDA LTM / Revenue): 15.1%

Target EV / EBITDA (hist percentile): 30.0x
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 3 785
Net Debt ($m): -373
EV (Enterprise Value): 3 412
EBITDA LTM (млн $): 78
EV / LTM EBITDA: 43.7x
Price to Book: 3.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-01-30zacks.com

Here's Why Veracyte (VCYT) Is a Great 'Buy the Bottom' Stock Now

2026-01-26zacks.com

Why Veracyte (VCYT) is Poised to Beat Earnings Estimates Again

2026-01-22zacks.com

Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term

2026-01-16seekingalpha.com

Veracyte: Profitable, De-Risked, And Ready To Run

2026-01-15seekingalpha.com

Veracyte, Inc. (VCYT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-29businesswire.com

Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference

2025-12-23zacks.com

Is This the Right Time to Add Veracyte Stock to Your Portfolio?

2025-12-02zacks.com

Why Veracyte (VCYT) is a Top Growth Stock for the Long-Term

2025-11-11zacks.com

VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up

2025-11-04seekingalpha.com

Veracyte, Inc. (VCYT) Q3 2025 Earnings Call Transcript
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-05 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2025-02-27 21:58:16 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44 2022-02-28 16:40:48 2021-02-22 16:18:16
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
revenue 132M 130M 446M 116M 114M 97M 361M 90M 90M 82M 297M 76M 220M 117M
costOfRevenue 43M 40M 148M 37M 39M 36M 113M 28M 30M 26M 102M 26M 74M 41M
grossProfit 89M 90M 298M 79M 76M 61M 248M 62M 61M 56M 195M 50M 145M 76M
grossProfitRatio 0.678 0.69 0.682 0.662 0.625 0.694 0.671 0.682 0.656
researchAndDevelopmentExpenses 16M 16M 69M 18M 16M 16M 57M 13M 13M 13M 41M 11M 30M 17M
generalAndAdministrativeExpenses 0 14M 178M 26M 48M 43M 158M 16M 25M 22M 77M 18M 101M 37M
sellingAndMarketingExpenses 0 43M 28M 23M 7M 6M 27M 24M 26M 26M 98M 26M 80M 52M
sellingGeneralAndAdministrativeExpenses 51M 57M 206M 48M 55M 49M 184M 41M 51M 49M 174M 43M 181M 89M
otherExpenses 0 22M 7M 0 -125 000 43 000 92M 40M -226 000 5M 21M 5M 16M 5M
operatingExpenses 66M 95M 282M 66M 71M 65M 334M 94M 69M 67M 236M 59M 227M 111M
costAndExpenses 109M 135M 430M 103M 110M 101M 447M 122M 98M 93M 338M 85M 301M 153M
interestIncome 3M 3M 11M 3M 3M 3M 7M 2M 1M 1M 2M 573 000 135 000 594 000
interestExpense 0 0 2000 1000 1000 0 15 000 2000 3000 7000 198 000 61 000 241 000 229 000
depreciationAndAmortization 5M 5M 23M 6M 6M 6M 27M 7M 7M 7M 29M 6M 21M 8M
ebitda 24M 7M 49M 23M 11M 1M -49M 45M -1M -4M -7M -3M -60M -27M
ebitdaratio 0.183 0.052 0.196 0.091 0.014 0.504 -0.013 -0.046 -0.044
operatingIncome 23M -5M 16M 12M 5M -4M -86M -32M -8M -10M -41M -10M -82M -35M
operatingIncomeRatio 0.175 -0.04 0.104 0.041 -0.044 -0.352 -0.089 -0.127 -0.128
totalOtherIncomeExpensesNet -4M 7M 10M 5M 3M 2M 9M 2M -226 000 2M 5M 805 000 254 000 480 000
incomeBeforeTax 19M 1M 26M 17M 7M -2M -77M -30M -8M -8M -36M -9M -82M -35M
incomeBeforeTaxRatio 0.143 0.01 0.145 0.064 -0.02 -0.33 -0.092 -0.098 -0.117
incomeTaxExpense -248 000 2M 2M 2M 2M -44 000 -2M -154 000 125 000 -2M 133 000 -152 000 -6M 0
netIncome 19M -980 000 24M 15M 6M -2M -74M -30M -8M -6M -37M -9M -76M -35M
netIncomeRatio 0.145 -0.008 0.131 0.05 -0.019 -0.329 -0.093 -0.069 -0.115
eps 0.243 -0.013 0.32 0.2 0.075 -0.025 -1.02 -0.41 -0.12 -0.079 -0.51 -0.12 -1.11 -0.66
epsdiluted 0.24 -0.013 0.19 0.074 -0.025 -0.41 -0.12 -0.079 -0.12
weightedAverageShsOut 79M 78M 76M 77M 77M 75M 73M 73M 72M 72M 72M 72M 68M 53M
weightedAverageShsOutDil 80M 80M 78M 78M 77M 75M 73M 73M 72M 72M 72M 72M 68M 53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-28 2021-02-22
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 11M 7M 2M -106 000 365 000
ebit 26M -77M -36M -81M -35M
nonOperatingIncomeExcludingInterest -10M -9M -5M -495 000 -709 000
netIncomeFromContinuingOperations 24M -74M -37M -76M -35M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 24M -74M -37M -76M -35M
epsDiluted 0.31 -1.02 -0.51 -1.11 -0.66

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-05 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2025-02-27 21:58:16 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44 2022-02-28 16:40:48 2021-02-22 16:18:16
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
cashAndCashEquivalents 316M 219M 239M 274M 236M 209M 216M 202M 191M 178M 154M 170M 173M 349M
shortTermInvestments 51M 101M 50M 0 0 0 0 0 0 0 25M 0 4M 0
cashAndShortTermInvestments 366M 321M 289M 274M 236M 209M 216M 202M 191M 178M 179M 170M 177M 349M
netReceivables 48M 51M 47M 49M 50M 47M 40M 39M 42M 45M 44M 40M 41M 18M
inventory 20M 25M 22M 20M 19M 18M 16M 16M 12M 13M 14M 14M 11M 5M
otherCurrentAssets 15M 18M 15M 14M 16M 16M 13M 14M 14M 15M 11M 15M -4M 0
totalCurrentAssets 449M 415M 372M 357M 321M 290M 286M 271M 259M 252M 249M 239M 243M 376M
propertyPlantEquipmentNet 56M 57M 71M 38M 40M 33M 31M 31M 31M 29M 31M 31M 31M 17M
goodwill 767M 773M 746M 762M 752M 754M 703M 693M 699M 700M 696M 677M 708M 3M
intangibleAssets 92M 96M 102M 109M 113M 116M 89M 124M 165M 170M 175M 177M 203M 60M
goodwillAndIntangibleAssets 860M 869M 848M 871M 865M 870M 792M 817M 864M 870M 871M 853M 911M 63M
longTermInvestments 2M 0 0 0 1M 1M 0 870 000 0 0 0 0 0 0
taxAssets 0 0 0 0 0 1 0 -870 000 0 0 0 0 0 0
otherNonCurrentAssets 1M 3M 9M 9M 7M 6M 7M 6M 7M 6M 6M 3M 3M 2M
totalNonCurrentAssets 919M 929M 928M 918M 913M 910M 829M 854M 902M 906M 908M 887M 945M 81M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 368M 1 344M 1 300M 1 275M 1 234M 1 200M 1 115M 1 125M 1 161M 1 157M 1 156M 1 126M 1 188M 457M
accountPayables 6M 11M 9M 10M 12M 12M 13M 13M 13M 16M 12M 11M 12M 3M
shortTermDebt 4M 6M 0 7M 14M 6M 0 5M 5M 4M 0 5M 1M 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 417 000 1M 2M 2M 2M 3M 2M 2M 2M 2M 3M 4M 5M 371 000
otherCurrentLiabilities 62M 57M 48M 51M 44M 37M 29M 38M 38M 34M 37M 38M 34M 9M
totalCurrentLiabilities 72M 76M 79M 70M 72M 58M 61M 57M 58M 56M 63M 58M 64M 17M
longTermDebt 36M 44M 0 12M 14M 8M 0 9M 10M 10M 0 12M 0 810 000
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 343 000 829 000
deferredTaxLiabilitiesNonCurrent 1M 1M 1M 1M 1M 1M 734 000 4M 5M 5M 5M 4M 6M 0
otherNonCurrentLiabilities 583 000 1M 972 000 15M 14M 14M 1M 1M 6M 6M 3M -694 000 7M 8M
totalNonCurrentLiabilities 38M 47M 45M 29M 29M 23M 10M 14M 20M 20M 19M 19M 27M 19M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 36M 51M 51M 20M 21M 8M 13M 14M 15M 14M 15M 15M 18M 12M
totalLiabilities 110M 123M 124M 99M 102M 81M 71M 71M 78M 76M 81M 78M 91M 36M
preferredStock 0 0 0 0 0 499M 0 474M 438M 0 0 0 0 0
commonStock 79 000 79 000 78 000 77 000 77 000 76 000 73 000 73 000 73 000 72 000 72 000 72 000 71 000 58 000
retainedEarnings -419M -438M -444M -449M -464M -470M -468M -440M -410M -402M -394M -390M -357M -282M
accumulatedOtherComprehensiveIncomeLoss -8M -12M -36M -21M -31M -29M -24M -34M -28M -27M -31M -54M -15M 0
othertotalStockholdersEquity 1 685M 1 671M 1 646M 1 627M 1 119M 1 054M 1 083M 1 510M 1 492M
totalStockholdersEquity 1 258M 1 221M 1 176M 1 176M 1 133M 1 119M 1 044M 1 054M 1 083M 1 081M 1 075M 1 048M 1 097M 421M
totalEquity 1 258M 1 221M 1 176M 1 176M 1 133M 1 119M 1 044M 1 054M 1 083M 1 081M 1 075M 1 048M 1 097M 421M
totalLiabilitiesAndStockholdersEquity 1 368M 1 344M 1 275M 1 234M 1 200M 1 125M 1 161M 1 157M 1 126M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 1 368M 1 344M 1 300M 1 275M 1 234M 1 200M 1 115M 1 125M 1 161M 1 157M 1 156M 1 126M 1 188M 457M
totalInvestments 52M 101M 50M 0 1M 1M 0 870 000 0 0 25M 0 4M 0
totalDebt 40M 51M 51M 20M 21M 14M 13M 14M 15M 14M 15M 17M 19M 12M
netDebt -275M -169M -188M -254M -215M -195M -204M -189M -176M -164M -140M -153M -154M -337M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-28 2021-02-22
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 47M 40M 44M 41M 18M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 17M 3M
totalPayables 9M 13M 12M 12M 3M
otherPayables 0 0 0 0 0
accruedExpenses 13M 12M 7M 9M 3M
capitalLeaseObligationsCurrent 8M 5M 4M 4M 2M
capitalLeaseObligationsNonCurrent 43M 8M 11M 14M 10M
treasuryStock 0 0 0 0 0
additionalPaidInCapital 1 656M 1 536M 1 500M 1 469M 703M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT VCYT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-11-05 2025-08-07 2024-11-07 2024-08-07 2024-05-08 2023-11-08 2023-08-09 2023-05-05 2022-11-03
acceptedDate 2025-11-05 08:15:57 2025-08-07 16:41:08 2025-02-27 21:58:16 2024-11-07 08:01:01 2024-08-07 08:11:25 2024-05-08 17:03:22 2024-02-29 08:06:41 2023-11-08 08:30:57 2023-08-09 16:07:39 2023-05-05 08:07:27 2023-02-28 17:48:53 2022-11-03 07:57:44 2022-02-28 16:40:48 2021-02-22 16:18:16
calendarYear 2025 2025 2024 2024 2023 2023 2023 2022 2022
period Q3 Q2 FY Q2 Q1 Q4 FY Q2 Q1 Q4 FY Q3 FY FY
netIncome 19M -980 000 24M 15M 6M -2M -74M -30M -8M -8M -37M -9M -76M -35M
depreciationAndAmortization 5M 5M 23M 6M 6M 6M 27M 7M 7M 7M 26M 6M 20M 8M
deferredIncomeTax -87 000 59 000 -233 000 -13 000 143 000 -120 000 -4M -968 000 125 000 0 133 000 -152 000 -6M 0
stockBasedCompensation 11M 11M 36M 9M 10M 8M 33M 7M 10M 8M 27M 7M 23M 13M
changeInWorkingCapital 6M 1M -21M 17M 6M -23M -4M -2M 6M -10M -16M 504 000 4M -481 000
accountsReceivables 425 000 3M -6M 2M -4M -6M 4M 3M 3M -1M -4M -1M -9M 955 000
inventory 221 000 -565 000 -6M -909 000 -963 000 -2M -2M -4M 2M 1M -3M 813 000 -1M 1M
accountsPayables -4M -4M -4M -1M -162 000 -2M -134 000 -607 000 -1M 2M 152 000 1M 5M 711 000
otherWorkingCapital 9M 3M -5M 17M 11M -13M -6M 614 000 3M -2M -9M 63 000 9M -3M
otherNonCashItems 3M 17M 13M -17M 28M 32M 66M 32M 1M 2M 8M 2M 4M 5M
netCashProvidedByOperatingActivities 45M 34M 75M 30M 30M -9M 44M 14M 17M -2M 8M 7M -32M -10M
investmentsInPropertyPlantAndEquipment -3M -1M -11M -2M -3M -2M -10M -3M -4M -993 000 -9M -2M -5M -3M
acquisitionsNet 0 0 5M 0 0 5M 0 0 0 0 0 0 -737M 0
purchasesOfInvestments 0 -50M -50M 0 0 0 -20M 0 0 -20M -34M 0 162M -1 000 000
salesMaturitiesOfInvestments 51M 0 0 0 0 0 45M 0 0 45M 13M 11M 3M 0
otherInvestingActivites 0 51M 0 0 0 0 0 0 0
netCashUsedForInvestingActivites 48M -224 000 -2M -3M 3M -3M -4M 24M 9M
debtRepayment 0 0 0 0 0 0 0 0 -3000
commonStockIssued 6M 0 -4M 1M 3M 3M 0 4M 0
commonStockRepurchased 0 0 0 5M -1M -4M 0 -2M 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -3M -566 000 10M -11 000 -4M -2M 397 000 -2M 1M
netCashUsedProvidedByFinancingActivities 3M -566 000 10M -11 000 -864 000 110 000 397 000 2M 1M
effectOfForexChangesOnCash 77 000 573 000 -424 000 146 000 -61 000 -108 000 163 000 -177 000 -7000 50 000 -592 000 -654 000 -2M 0
netChangeInCash 96M 33M 23M 39M 27M -7M 62M 11M 13M 24M -19M 17M -176M 190M
cashAtEndOfPeriod 316M 221M 241M 275M 236M 209M 217M 203M 192M 179M 155M 171M 174M 350M
cashAtBeginningOfPeriod 219M 188M 217M 237M 209M 216M 155M 192M 179M 155M 174M 154M 350M 160M
operatingCashFlow 45M 34M 75M 30M 30M -9M 44M 14M 17M -2M 8M 7M -32M -10M
capitalExpenditure -3M -1M -11M -2M -3M -2M -10M -3M -4M -993 000 -9M -2M -5M -3M
freeCashFlow 42M 32M 64M 28M 27M -11M 34M 11M 13M -3M -1M 5M -37M -13M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-29 2023-03-01 2022-02-28 2021-02-22
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 0 0 0 -162M 0
netCashProvidedByInvestingActivities -56M 15M -29M -739M -4M
netDebtIssuance 0 0 -1M 0 -100 000
longTermNetDebtIssuance 0 0 -1M 0 -100 000
shortTermNetDebtIssuance 0 0 0 0 0
netStockIssuance 20M 0 0 594M 194M
netCommonStockIssuance 20M 0 0 594M 194M
commonStockIssuance 20M 0 0 594M 194M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities -15M 3M 5M 2M 10M
netCashProvidedByFinancingActivities 5M 3M 3M 596M 204M
incomeTaxesPaid 2M 2M 570 000 112 000 112 000
interestPaid 0 0 9000 9000 13 000

Earning call transcript

2025 q3
2025-11-04 ET (fiscal 2025 q3)
2025 q2
2025-08-07 ET (fiscal 2025 q2)
2025 q1
2025-05-08 ET (fiscal 2025 q1)
2024 q4
2025-02-24 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q2
2024-08-06 ET (fiscal 2024 q2)
2024 q1
2024-05-07 ET (fiscal 2024 q1)
2023 q4
2024-02-22 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-08 ET (fiscal 2023 q2)
2023 q1
2023-05-04 ET (fiscal 2023 q1)
2022 q4
2023-02-23 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-02 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-15 13:00 ET
Veracyte Secures Medicare Coverage for TrueMRD Monitoring Test in Muscle-Invasive Bladder Cancer
2026-05-05 20:05 ET
Veracyte Announces First Quarter 2026 Financial Results
2026-04-28 ET
Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers
2026-04-14 ET
Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026
2026-03-16 ET
Veracyte Names Kevin Haas as Chief Development and Technology Officer
2026-02-25 ET
Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results
2026-02-24 ET
Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium
2026-02-19 ET
Veracyte to Participate in Upcoming Investor Conferences
2026-02-04 22:15 ET
Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
2026-01-11 ET
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results
2025-12-29 ET
Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference
2025-11-06 ET
Veracyte to Participate in Upcoming Investor Conferences
2025-11-04 ET
Veracyte Announces Third Quarter 2025 Financial Results
2025-11-03 21:15 ET
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing
2025-10-15 ET
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025
2025-09-28 ET
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer
2025-09-24 ET
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025
2025-09-09 ET
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting
2025-08-29 ET
Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
2025-08-27 ET
Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
2025-08-26 ET
Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test
2025-07-24 ET
Veracyte Set to Join S&P SmallCap 600
2025-07-17 ET
Veracyte to Release Second Quarter 2025 Financial Results on August 6, 2025
2025-07-08 ET
Veracyte Announces that Multiple Afirma GRID Studies Will Be Presented at ENDO 2025
2025-05-28 ET
Veracyte Announces Multiple Abstracts To Be Presented at ASCO, Demonstrating Power of Decipher GRID to Advance New Prostate and Bladder Cancer Research
2025-05-20 ET
Veracyte to Participate in Upcoming Investor Conferences
2025-05-07 ET
Veracyte Announces First Quarter 2025 Financial Results
2025-04-25 ET
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer
2025-04-22 ET
Veracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual Meeting
2025-04-21 ET
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release
2025-04-16 ET
Veracyte to Release First Quarter 2025 Financial Results on May 7, 2025
2025-03-25 ET
New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer
2025-03-19 ET
Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25
2025-02-24 ET
Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results
2025-02-19 ET
Veracyte to Participate in Upcoming Investor Conferences
2025-02-14 ET
New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research
2025-02-11 ET
Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium
2025-02-05 ET
New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer
2025-02-04 ET
Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025
2024-12-05 ET
Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines
2024-11-06 21:05 ET
Veracyte Announces Third Quarter 2024 Financial Results
2024-10-02 12:20 ET
New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men
2024-09-15 12:45 ET
New Data Presented at ESMO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer
2024-09-04 20:05 ET
Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors
2024-08-26 13:00 ET
Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle
2024-08-06 20:05 ET
Veracyte Announces Second Quarter 2024 Financial Results
2024-07-17 21:00 ET
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
2024-06-03 20:05 ET
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
2024-05-22 20:05 ET
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
2024-05-15 21:04 ET
Veracyte to Participate in Upcoming Investor Conferences
2024-05-07 20:05 ET
Veracyte Announces First Quarter 2024 Financial Results
2024-05-06 20:05 ET
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
2024-04-22 21:00 ET
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
2024-04-22 12:30 ET
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
2024-04-16 12:30 ET
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
2024-02-27 22:55 ET
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
2024-02-22 21:05 ET
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
2024-02-21 22:00 ET
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
2024-02-08 13:00 ET
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
2024-02-06 13:15 ET
Veracyte Completes Acquisition of C2i Genomics
2024-01-08 13:00 ET
Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform
2023-12-12 21:30 ET
Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2023-12-01 21:05 ET
Real-World Data Presented at SUO 2023 Show that Veracyte’s Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress
2023-11-29 13:30 ET
Clinical Validation Data Published in CHEST Demonstrate that Veracyte’s Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules
2023-11-22 13:30 ET
Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023
2023-11-07 21:05 ET
Veracyte Announces Third Quarter 2023 Financial Results
2023-11-07 21:00 ET
Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally
2023-11-02 12:15 ET
Veracyte to Participate in the Stephens Annual Investment Conference
2023-10-27 12:30 ET
Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
2023-10-17 12:15 ET
Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023
2023-10-12 13:00 ET
New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracyte’s Envisia Genomic Classifier for Patients with Interstitial Lung Disease
2023-10-04 20:05 ET
New Data from Phase 3 Trial Further Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier
2023-09-28 20:05 ET
New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracyte’s Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer
2023-09-28 12:15 ET
Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023
2023-09-27 13:00 ET
Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer
2023-09-21 20:05 ET
Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting
2023-09-07 20:05 ET
Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Company’s Tests
2023-09-06 12:15 ET
Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies
2023-08-29 12:15 ET
Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-22 12:15 ET
Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer
2023-08-15 20:15 ET
Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego
2023-08-08 20:05 ET
Veracyte Announces Second Quarter 2023 Financial Results
2023-08-01 12:15 ET
Study Published in JNCI Cancer Spectrum Demonstrates Real-World Utility of Veracyte’s Decipher Prostate Genomic Classifier in Prostate Cancer Treatment
2023-07-19 21:00 ET
Veracyte to Release Second Quarter 2023 Financial Results on August 8, 2023
2023-06-20 12:31 ET
New Data Suggest Veracyte’s Afirma Molecular Testing Capabilities Can Help Advance Scientific Understanding of Thyroid Nodules and Cancer
2023-06-12 12:31 ET
Veracyte Announces Afirma-Focused Abstracts to Be Presented at ENDO 2023
2023-05-25 21:13 ET
New Data To Be Shared at 2023 ASCO Demonstrate Power of Veracyte’s Decipher GRID To Help Advance Molecular Understanding of Prostate Cancer
2023-05-24 13:00 ET
New Data Presented at ATS 2023 Reinforce Clinical Utility of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
2023-05-23 21:00 ET
Veracyte to Participate in Upcoming Investor Conferences
2023-05-12 10:15 ET
Veracyte Announces that New Data Show Use of the Prosigna Test Significantly Changed Treatment Decisions for Patients with Early-Stage Breast Cancer
2023-05-04 20:05 ET
Veracyte Announces First Quarter 2023 Financial Results
2023-05-04 13:45 ET
New Data Being Presented at AACE 2023 Help Elucidate Cancer Risk of TERT Promoter Gene Mutations in Patients with Indeterminate Thyroid Nodules
2023-05-03 21:44 ET
New Data Published In Cancer Suggest Decipher GRID-Derived Gene Expression Signature Could Enable More Personalized Treatment for Prostate Cancer Patients
2023-05-03 12:30 ET
Veracyte Announces Release of Inaugural ESG Report
2023-05-02 20:05 ET
Data Published in "The Red Journal” Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy in Men with Intermediate-Risk Prostate Cancer
2023-05-01 21:35 ET
Three Abstracts Focusing on the Clinical Utility of Veracyte’s Genomic Tests in ILD and Lung Cancer To Be Presented at ATS 2023 International Conference
2023-04-29 20:31 ET
Findings From Two Large-Scale, Real-World Data Sets Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
2023-04-27 20:05 ET
Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate and Other Cancers To Be Presented at the 2023 ASCO Annual Meeting
2023-04-17 12:30 ET
New Data Reinforce Ability of Veracyte’s Decipher Prostate Genomic Classifier To Help Identify Prostate Cancer Patients Who Would Benefit from Treatment Intensification
2023-04-13 21:00 ET
Veracyte to Release First Quarter 2023 Financial Results on May 4, 2023
2023-04-12 12:30 ET
Veracyte Announces Seven Abstracts for Its Decipher Urologic Cancer Tests To Be Presented at 2023 AUA Annual Meeting
2023-03-15 20:15 ET
Veracyte Announces Three Abstracts to Be Presented at AACR Annual Meeting 2023 Highlighting the Company’s Multi-Omics Capabilities and Tools for Biopharma Partners
2023-03-11 17:11 ET
Veracyte Provides Statement on Impact of Events Surrounding Silicon Valley Bank
2023-02-27 22:00 ET
Veracyte to Participate in Upcoming Investor Conferences
2023-02-22 21:05 ET
Veracyte Announces Fourth Quarter and Full-Year 2022 Financial Results
2023-02-15 13:36 ET
Data Published in “The Red Journal” Validate Prognostic Value of Veracyte’s Decipher Prostate Genomic Classifier for Men with High-Risk Prostate Cancer
2023-02-13 22:23 ET
New Data To Be Presented at 2023 ASCO GU Suggest Decipher GRID-Derived Gene Expression Signature Can Help Personalize Prostate Cancer Treatment
2023-02-06 22:00 ET
Veracyte to Release Fourth Quarter and Full-Year 2022 Financial Results on February 22, 2023
2023-02-01 21:05 ET
Veracyte Announces Multiple Decipher Urologic Testing Abstracts to be Presented at the 2023 ASCO Genitourinary (GU) Cancers Symposium
2023-02-01 13:32 ET
Veracyte Announces New Data Suggesting Afirma Testing Can Help Personalize Care for Patients with Thyroid Nodules
2022-12-15 21:05 ET
Data Published in JCEM Demonstrate Strong Real-World Performance of Veracyte’s Afirma GSC in Thyroid Cancer Diagnosis
2022-11-02 20:05 ET
Veracyte Announces Third Quarter 2022 Financial Results
2022-11-01 21:11 ET
Veracyte Announces Three Abstracts to Be Presented at SITC 2022 Annual Meeting
2022-10-27 21:00 ET
Veracyte to Participate in the Credit Suisse 31st Annual Healthcare Conference
2022-10-25 12:30 ET
New Data Suggest Decipher GRID-Derived Genomic Signature Can Help Identify Men with Prostate Cancer Who Should Receive High-Dose Radiotherapy
2022-10-24 12:30 ET
Veracyte Data Presented at ATA Annual Meeting Provide New Insights into Molecular Underpinnings of Thyroid Cancer
2022-10-18 20:05 ET
New Data Presented at CHEST 2022 Reinforce Clinical Value of Veracyte’s Genomic Tests in Interstitial Lung Disease and Lung Cancer
2022-10-13 21:00 ET
Veracyte to Release Third Quarter 2022 Financial Results on November 2, 2022
2022-09-22 12:55 ET
New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men
2022-09-13 12:30 ET
Veracyte Names John Leite, Ph.D., as General Manager of Pulmonology & Market Access
2022-09-11 06:30 ET
New Data Presented at ESMO 2022 Show Veracyte’s Decipher Prostate Genomic Classifier May Help Inform Personalized Treatment Decisions in Men with Advanced Prostate Cancer
2022-09-07 20:54 ET
New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
2022-09-01 21:00 ET
Veracyte to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
2022-08-31 11:00 ET
Veracyte Announces Seven Abstracts to Be Presented at ESMO Congress 2022
2022-08-29 15:19 ET
New Data in Nature Medicine Suggest Pre-Treatment Tumor Microenvironment Can Impact Response for CAR T-Cell Therapy in Patients with Large B-Cell Lymphoma
2022-08-11 20:05 ET
Veracyte Appoints Eliav Barr, M.D., to Its Board of Directors
2022-08-02 20:05 ET
Veracyte Announces Second Quarter 2022 Financial Results
2022-07-20 20:15 ET
Veracyte Announces New Clinical Validation Data for RNA Sequencing-Based Afirma Medullary Thyroid Cancer Classifier Published in Thyroid
2022-07-14 20:30 ET
Veracyte to Release Second Quarter 2022 Financial Results on August 2, 2022
2022-07-13 20:15 ET
New Data Published in PLOS ONE Validate the Clinical Performance of Veracyte’s Percepta Genomic Sequencing Classifier in Lung Cancer Diagnosis
2022-06-27 12:15 ET
Veracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year
2022-06-20 12:15 ET
New Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical Practice
2022-06-03 12:30 ET
Data Published in Annals of Oncology Reinforce Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier for Informing Treatment of Men Experiencing Prostate Cancer Progression
2022-05-31 20:20 ET
Veracyte Announces that New Data Show Immunoscore IC Assay May Predict Patients Likely to Benefit from Addition of Immunotherapy to Standard First-Line Therapy for Metastatic Colorectal Cancer
2022-05-26 21:10 ET
 New Data to be Shared at ASCO 2022 Underscore Clinical Utility of Decipher Prostate Genomic Classifier
2022-05-26 21:05 ET
Veracyte Announces New Data to be Presented at ASCO 2022 Showing Immunoscore IC Assay’s Ability to Identify Patients with NSCLC Who May Benefit from Immune Checkpoint Inhibitors
2022-05-26 12:15 ET
Veracyte to Present at Upcoming Investor Conferences
2022-05-16 20:17 ET
Veracyte Announces New Data Reinforcing Percepta Nasal Swab Test’s Clinical Performance and Utility in Lung Cancer Risk Assessment
2022-05-12 20:36 ET
Updated AUA/ASTRO Guideline Includes Supportive Statement for Use of Genomic Tests, Including Decipher Prostate, for Men With Localized Prostate Cancer
2022-05-12 12:30 ET
Veracyte Announces that Data for Its Genomic and Immuno-Oncology Offerings Will Be Highlighted at the 2022 ASCO Annual Meeting
2022-05-04 12:30 ET
Veracyte Announces New Consensus Data from PROCURE Study Presented at ESMO Breast Cancer 2022
2022-05-03 20:05 ET
Veracyte Announces First Quarter 2022 Financial Results
2022-05-02 20:18 ET
Envisia Genomic Classifier Highlighted in Updated Clinical Practice Guideline Regarding Idiopathic Pulmonary Fibrosis Diagnosis
2022-04-28 20:15 ET
Veracyte Announces New Urologic Cancer Data To Be Presented at AUA 2022 International Conference
2022-04-26 20:05 ET
Veracyte Announces New Performance Data for the Percepta Nasal Swab Test To Be Presented at ATS 2022 International Conference
2022-04-19 12:15 ET
Veracyte to Release First Quarter 2022 Financial Results on May 3, 2022
2022-03-01 21:05 ET
Veracyte to Participate in the Cowen 42nd Annual Health Care Conference
2022-02-28 21:05 ET
Veracyte Announces Fourth Quarter and Full-Year 2021 Financial Results
2022-02-28 13:30 ET
Veracyte Appoints Annie McGuire as General Counsel
2022-02-22 13:30 ET
Veracyte Appoints Jonathan Wygant as Chief Accounting Officer
2022-02-15 13:30 ET
Veracyte to Release Fourth Quarter and Full-Year 2021 Financial Results on February 28, 2022
2022-02-15 00:30 ET
New Data Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier To Help Guide Therapy In Men with Intermediate-Risk Prostate Cancer
2022-02-08 21:05 ET
Veracyte to Participate in 11th Annual SVB Leerink Global Healthcare Conference
2022-01-31 13:25 ET
Veracyte Announces New Data to be Presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium
2022-01-24 13:30 ET
New Data Suggest Veracyte’s Percepta Genomic Sequencing Classifier Can Help Accelerate Timely Treatment for Patients with Early-Stage Lung Cancer
2022-01-06 13:30 ET
Veracyte Announces Key Leadership Promotions to Advance Its Strategic Global Vision
2021-12-14 21:05 ET
Veracyte Announces Publication of Data Demonstrating Clinical Utility of Its Envisia Genomic Classifier to Improve IPF Diagnosis
2021-11-24 09:32 ET
Veracyte Announces Further European Reimbursement Expansion for Prosigna Breast Cancer Test
2021-11-13 12:00 ET
Veracyte Announces New Data on Immuno-Oncology Offerings Presented at SITC 2021
2021-11-09 21:05 ET
Veracyte Announces Third Quarter 2021 Financial Results
2021-11-05 12:15 ET
Veracyte Announces Immunoscore Colon Cancer Test Included in ESMO Clinical Practice Guidelines Adapted for Pan-Asia
2021-11-03 12:15 ET
New Publication Reinforces Clinical Utility of Afirma Genomic Sequencing Classifier in Thyroid Cancer Diagnosis
2021-11-02 12:15 ET
Veracyte Announces New Data To Be Presented at SITC 2021 Will Highlight Company’s Immuno-Oncology Capabilities
2021-10-26 13:25 ET
New Data Demonstrate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier in Tailoring Treatment for Prostate Cancer Patients Experiencing Progression After Surgery
2021-10-25 14:30 ET
Data Presented at ASTRO 2021 Validate Prognostic Value of Decipher Prostate Genomic Test in Newly Diagnosed, Clinically High-Risk Prostate Cancer
2021-10-14 12:35 ET
New Data to be Presented at ASTRO 2021 Further Validate Clinical Utility of Veracyte’s Decipher Prostate Genomic Classifier
2021-10-13 12:55 ET
New Publication Demonstrates Ability of Veracyte’s Decipher Bladder Test to Identify Tumors Most Likely to Respond to Chemotherapy
2021-10-12 20:05 ET
Veracyte to Release Third Quarter 2021 Financial Results on November 9, 2021
2021-10-11 20:41 ET
New Clinical Utility Data Confirm Veracyte’s Envisia Genomic Classifier Increases Accuracy and Confidence in IPF Diagnosis
2021-10-11 12:15 ET
Veracyte Announces New Expanded Data at CHEST Underscoring Percepta Nasal Swab Test’s Ability to Improve Early Lung Cancer Assessment
2021-10-06 12:30 ET
New Data to be Presented at CHEST 2021 Showcase Clinical Performance of Veracyte’s Genomic Diagnostic Tests in Lung Cancer and Interstitial Lung Disease
2021-09-14 20:05 ET
Veracyte Announces that New NCCN Guidelines Uniquely Recommend Use of Decipher Prostate Genomic Test Score to Guide Specific Treatment for Men Following Radical Prostatectomy
2021-09-01 12:35 ET
Veracyte Further Strengthens Medical Team with Appointment of Joshua Klopper, M.D., as Medical Director of Endocrinology
2021-08-31 12:15 ET
Veracyte to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
2021-08-23 14:33 ET
Veracyte Named a San Francisco Bay Area “Top Workplace” for Eighth Consecutive Year
2021-08-03 12:00 ET
Veracyte Completes Acquisition of HalioDx
2021-07-29 20:05 ET
Veracyte Announces Second Quarter 2021 Financial Results
2021-07-27 20:05 ET
New Study Suggests Decipher Prostate Biopsy Test May Help Guide Use of Active Surveillance in Prostate Cancer
2021-07-12 12:30 ET
Veracyte Appoints Rebecca Chambers as Executive Vice President and Chief Financial Officer, Further Positioning Company for Global Growth
2021-07-08 20:05 ET
Veracyte to Release Second Quarter 2021 Financial Results on July 29, 2021
2021-07-08 12:30 ET
Veracyte Announces Key Appointments to Executive Leadership Team, Supporting Global Expansion
2021-07-01 12:45 ET
Veracyte Announces Two Pre-Eminent Physician Appointments, Further Strengthening Medical Team
2021-06-14 12:45 ET
New Data Published in JAMA Oncology Demonstrate Prognostic Utility of Veracyte’s Decipher Prostate Genomic Classifier in Locally Advanced Prostate Cancer
2021-06-04 13:24 ET
Veracyte Receives Final Medicare Coverage Policies for Decipher Bladder
2021-06-02 19:00 ET
CORRECTING and REPLACING Veracyte to Present at Upcoming Investor Conferences
2021-06-01 11:00 ET
Veracyte to Acquire HalioDx, Positioning for Global Cancer Diagnostics Growth
2021-05-26 19:00 ET
Veracyte to Present at Upcoming Investor Conferences
2021-05-26 13:05 ET
Veracyte Announces New Data Demonstrating Afirma Xpression Atlas Identifies Clinically Relevant Gene Fusions in Thyroid Cancer FNA Samples
2021-05-25 13:00 ET
Veracyte Announces New Data at ASCO 2021 Reinforcing Prognostic Utility of Decipher Prostate Genomic Classifier
2021-05-19 21:00 ET
Veracyte Announces New Pivotal Clinical Validation Data at ASCO Showing Noninvasive Nasal Swab Test Can Significantly Improve Early Lung Cancer Detection
2021-05-18 21:15 ET
Veracyte to Present at Upcoming Investor Conferences
2021-05-14 20:35 ET
Veracyte Announces Data Reinforcing the Diagnostic Performance and Utility of the Envisia Genomic Classifier in ILD Diagnosis
2021-05-14 16:45 ET
Veracyte Announces Data Showing Percepta Genomic Atlas Detects Gene Alterations Targeted in Lung Cancer Treatment, Using Diagnostic Biopsy
2021-05-10 20:10 ET
Veracyte, Inc. Announces CEO Succession Plan
2021-05-10 20:05 ET
Veracyte Announces First Quarter 2021 Financial Results
2021-05-04 20:45 ET
Veracyte Announces New Data Relating to Prosigna Breast Cancer Test to Be Presented at ESMO Breast Cancer Virtual Congress
2021-04-29 12:30 ET
Veracyte to Unveil Practice-Changing Genomic Diagnostics Data Across Multiple Oncology Indications at 2021 ASCO
2021-04-27 20:35 ET
Veracyte Announces Publication of Study Showing Robust Performance of Percepta GSC in Improving Lung Cancer Diagnosis
2021-04-20 17:00 ET
Veracyte to Release First Quarter 2021 Financial Results on May 10, 2021
2021-04-19 12:30 ET
Veracyte Announces Data for Pulmonology Portfolio to be Presented at American Thoracic Society 2021 International Conference
2021-04-15 20:05 ET
Veracyte Announces Retirement of CFO and Preliminary First Quarter 2021 Financial Results
2021-04-14 12:30 ET
Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
2021-04-02 12:15 ET
Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
2021-03-22 12:15 ET
Veracyte Appoints Muna Bhanji to Its Board of Directors
2021-03-15 12:30 ET
Veracyte Completes Acquisition of Decipher Biosciences
2021-03-10 22:15 ET
Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
2021-02-18 21:05 ET
Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
2021-02-17 21:05 ET
Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
2021-02-11 21:05 ET
Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
2021-02-10 13:15 ET
Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
2021-02-09 21:15 ET
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-02-05 03:45 ET
Veracyte Announces Pricing of Upsized Public Offering of 7,432,433 Shares of Common Stock
2021-02-03 21:32 ET
Veracyte Announces Proposed Public Offering of Common Stock
2021-02-03 12:05 ET
Veracyte to Acquire Decipher Biosciences
2021-02-03 12:00 ET
Veracyte Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results
2021-01-06 19:00 ET
Veracyte to Participate in 23rd Annual Needham Virtual Growth Conference
2020-12-22 13:15 ET
Bayer and Veracyte Announce Precision Oncology Collaboration in Thyroid Cancer
2020-12-21 13:15 ET
Veracyte Announces ISO 13485:2016 Certification for Its In Vitro Diagnostics Quality Management System
2020-12-16 17:00 ET
Veracyte Announces New Preliminary Data for Its In-Development Lung Cancer Portfolio Tests
2020-12-15 13:15 ET
Veracyte Announces Expansion of Collaboration with the Lung Cancer Initiative at Johnson & Johnson
2020-12-03 19:30 ET
Veracyte to Host Virtual Lung Cancer R&D Day on Wednesday, December 16, 2020
2020-11-23 21:05 ET
Veracyte to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference
2020-11-17 13:30 ET
Veracyte Announces New General Manager Structure to Advance Global Expansion
2020-11-05 08:05 ET
Prosigna Breast Cancer Assay Now Approved for Reimbursement in Germany
2020-11-02 21:05 ET
Veracyte Announces Third Quarter 2020 Financial Results
2020-10-30 12:15 ET
Veracyte Announces New Data Published in Journal of Clinical Oncology Suggest the Prosigna Breast Cancer Test’s Genomic Underpinning Drives Prognostic Performance
2020-10-22 20:05 ET
Veracyte Announces Publication of Manuscript Describing Scientific Rigor Behind Next-Generation Percepta Genomic Sequencing Classifier
2020-10-19 12:15 ET
Veracyte Announces New Data Reinforcing Foundational Technology of Nasal Swab Test for Early Lung Cancer Detection Presented at CHEST Annual Meeting 2020
2020-10-14 20:05 ET
Veracyte Announces Two Presentations to Be Shared at CHEST Annual Meeting 2020
2020-10-07 12:15 ET
Veracyte to Release Third Quarter 2020 Financial Results on November 2, 2020
2020-09-24 12:15 ET
Veracyte Receives ADLT Status for Envisia Genomic Classifier From Centers for Medicare and Medicaid Services
2020-09-15 20:30 ET
Veracyte to Present at Two Investor Conferences
2020-09-14 17:45 ET
Veracyte Announces Promotion of Richard T. Kloos, M.D. To Executive Medical Director
2020-09-11 12:15 ET
Veracyte Announces Initiation of Consensus Study Exploring Medical Utility of Multiple Breast Cancer Genomic Tests
2020-09-04 12:15 ET
Veracyte to Present at Upcoming Investor Conferences
2020-08-24 12:15 ET
Veracyte Named a San Francisco Bay Area “Top Workplace” for Seventh Consecutive Year
2020-08-07 20:15 ET
Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-08-05 20:15 ET
Veracyte Announces New Real-World Data Reinforcing the Potential Clinical Value of Percepta and Envisia Classifiers to Improve Diagnosis of Serious Lung Diseases
2020-08-05 12:15 ET
Veracyte Announces Positive Clinical Utility Data for Percepta Classifier Published in CHEST
2020-08-04 23:27 ET
Veracyte Announces Pricing of Public Offering of 6,000,000 Shares of Common Stock
2020-08-03 20:10 ET
Veracyte Announces Proposed Public Offering of Common Stock
2020-07-30 20:05 ET
Veracyte Announces Second Quarter 2020 Financial Results
2020-07-30 12:15 ET
Veracyte Announces Data Published in AJRCCM Showing That the Envisia Genomic Classifier Improves Physicians’ Ability to Diagnose IPF Without Surgery
2020-07-29 12:15 ET
Veracyte and MAVIDx Announce Agreement for MAVIDx to Develop Ultra-High Volume COVID-19 Testing on the nCounter System
2020-07-27 12:15 ET
Veracyte Appoints Jens Holstein to Board of Directors and James (Jim) Erlinger as Executive Vice President, General Counsel and Secretary
2020-07-16 12:15 ET
Veracyte to Release Second Quarter 2020 Financial Results on July 30, 2020
2020-06-11 11:30 ET
Veracyte Announces Clinical Utility Study Published in CHEST Demonstrates Envisia Genomic Classifier’s Ability to Improve IPF Diagnosis
2020-06-09 12:15 ET
Veracyte Announces De Novo Classification Request to FDA for the nCounter Dx LymphMark Assay
2020-05-27 12:15 ET
Veracyte to Present at the William Blair 40th Annual Growth Stock Conference
2020-05-21 12:15 ET
Veracyte to Present at the Jefferies Virtual Healthcare Conference
2020-05-14 12:15 ET
CareDx and Veracyte Announce Exclusive Partnership for Transplant Rejection Testing on nCounter System
2020-05-07 20:05 ET
Veracyte to Present at the UBS Virtual Global Healthcare Conference
2020-05-06 20:05 ET
Veracyte Announces First Quarter 2020 Financial Results
2020-05-01 12:15 ET
Veracyte Launches “More About You” Campaign to Educate Patients About Thyroid Cancer Diagnosis
2020-04-23 12:15 ET
CORRECTING and REPLACING Veracyte and Yale Announce Exclusive License to Advance First Genomic Monitoring Test for Idiopathic Pulmonary Fibrosis
2020-04-16 20:30 ET
Veracyte Announces Preliminary First Quarter 2020 Financial Results and Provides Business Update in Response to COVID-19 Pandemic
2020-04-07 12:15 ET
Veracyte Names Tracy Morris as Vice President of Corporate Communications and Investor Relations
2020-04-01 12:15 ET
Veracyte Announces Novel Gene Fusion Detection with the Afirma Xpression Atlas, Which May Inform Targeted Treatment Decisions for Thyroid Cancer Patients
2020-03-02 16:00 ET
Veracyte Announces Publication of Nearly 700-Patient Study Using Prosigna Breast Cancer Test to Identify Patients Likely to Benefit from Aggressive Chemotherapy
2020-02-25 21:05 ET
Veracyte Announces Fourth Quarter and Full-Year 2019 Financial Results and Provides 2020 Financial Outlook
2020-02-13 13:15 ET
Veracyte to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-06 18:30 ET
Veracyte to Release Fourth Quarter and Full-Year 2019 Financial Results on February 25, 2020
2020-01-08 13:15 ET
Veracyte Announces Biopharmaceutical Collaboration with Acerta Pharma
2019-12-03 22:00 ET
Veracyte Acquires Exclusive License to NanoString Diagnostics Platform, Positioning Veracyte To Expand Its Genomic Testing Business Globally
2019-11-02 13:30 ET
Veracyte Announces New Data That Advance Understanding of Genomic Alterations Targeted by Precision Medicine Therapies for Thyroid Cancer
2019-10-30 12:15 ET
Veracyte Announces New Data Characterizing Genomic Alterations in Thyroid Cancer To Be Presented at 89th Annual Meeting of the American Thyroid Association
2019-10-22 20:15 ET
Veracyte Announces Third Quarter 2019 Financial Results and Business Progress
2019-10-22 11:00 ET
Veracyte Announces New Clinical Data Showing First-Ever Noninvasive Nasal Swab Test Can Enable Early Lung Cancer Detection and Diagnosis
2019-10-21 20:15 ET
Veracyte Announces Clinical Data Demonstrating Clinical Validity and Utility of Percepta Classifier in Lung Cancer Diagnosis When Bronchoscopy Results Are Inconclusive
2019-10-21 13:57 ET
Veracyte Announces New Data Demonstrating That Envisia Genomic Classifier Improves IPF Diagnosis
2019-10-08 20:30 ET
Veracyte to Release Third Quarter 2019 Financial Results and Business Progress on October 22, 2019
2019-10-07 12:00 ET
Veracyte to Announce New Clinical Data for First Noninvasive Nasal Swab Test to Target Early Lung Cancer Detection at CHEST Annual Meeting 2019
2019-09-11 15:04 ET
Veracyte Announces Publication of Clinical and Analytical Validation Data for Afirma Xpression Atlas

SEC forms

Show financial reports only

SEC form 8
2026-02-25 16:07 ET
Veracyte published news for 2025 q4
SEC form 8
2026-02-25 16:07 ET
Veracyte reported for 2025 q4
SEC form 8
2025-11-04 16:08 ET
Veracyte published news for 2025 q3
SEC form 8
2025-11-04 16:08 ET
Veracyte reported for 2025 q3
SEC form 10
2025-08-07 20:41 ET
Veracyte reported for 2025 q2
SEC form 8
2025-08-06 20:08 ET
Veracyte published news for 2025 q2
SEC form 8
2025-08-06 20:08 ET
Veracyte published news for 2025 q2
SEC form 10
2025-05-08 12:06 ET
Veracyte published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Veracyte published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Veracyte published news for 2025 q1
SEC form 8
2025-05-07 20:07 ET
Veracyte reported for 2025 q1
SEC form 10
2025-02-28 02:58 ET
Veracyte published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Veracyte published news for 2024 q4
SEC form 8
2025-02-24 16:11 ET
Veracyte published news for 2024 q4
SEC form 8
2025-02-24 16:11 ET
Veracyte reported for 2024 q4
SEC form 10
2024-11-07 08:01 ET
Veracyte published news for 2024 q3
SEC form 8
2024-11-06 16:11 ET
Veracyte published news for 2024 q3
SEC form 8
2024-11-06 16:11 ET
Veracyte published news for 2024 q3
SEC form 10
2024-08-07 08:11 ET
Veracyte published news for 2024 q2
SEC form 10
2024-08-07 00:00 ET
Veracyte published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Veracyte published news for 2024 q2
SEC form 8
2024-08-06 16:16 ET
Veracyte reported for 2024 q2
SEC form 10
2024-05-08 00:00 ET
Veracyte published news for 2024 q1
SEC form 8
2024-05-07 16:10 ET
Veracyte published news for 2024 q1
SEC form 8
2024-05-07 16:10 ET
Veracyte reported for 2024 q1
SEC form 10
2024-02-29 00:00 ET
Veracyte published news for 2023 q4
SEC form 8
2024-02-22 16:12 ET
Veracyte published news for 2023 q4
SEC form 8
2024-02-22 16:12 ET
Veracyte reported for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Veracyte published news for 2023 q4
SEC form 8
2024-01-08 00:00 ET
Veracyte published news for 2023 q4
SEC form 10
2023-11-08 08:30 ET
Veracyte published news for 2023 q3
SEC form 10
2023-11-08 00:00 ET
Veracyte published news for 2023 q3
SEC form 8
2023-11-07 16:09 ET
Veracyte reported for 2023 q3
SEC form 10
2023-08-09 16:07 ET
Veracyte published news for 2023 q2
SEC form 10
2023-08-09 00:00 ET
Veracyte published news for 2023 q2
SEC form 6
2023-08-08 16:11 ET
Veracyte reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Veracyte published news for 2023 q2
SEC form 6
2023-06-09 17:01 ET
Veracyte published news for 2023 q1
SEC form 10
2023-05-05 00:00 ET
Veracyte published news for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Veracyte published news for 2023 q1
SEC form 10
2023-03-01 00:00 ET
Veracyte reported for 2022 q4
SEC form 10
2023-02-28 17:48 ET
Veracyte reported for 2022 q4
SEC form 6
2023-02-22 16:08 ET
Veracyte published news for 2022 q4
SEC form 8
2023-02-22 00:00 ET
Veracyte reported for 2022 q4
SEC form 6
2023-02-10 16:44 ET
Veracyte published news for 2022 q4
SEC form 6
2022-12-14 08:25 ET
Veracyte published news for 2022 q3
SEC form 10
2022-11-03 07:57 ET
Veracyte reported for 2022 q3
SEC form 10
2022-11-03 00:00 ET
Veracyte reported for 2022 q3
SEC form 6
2022-11-02 16:11 ET
Veracyte published news for 2022 q3
SEC form 8
2022-11-02 00:00 ET
Veracyte reported for 2022 q3
SEC form 6
2022-09-07 16:56 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-11 16:26 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-11 16:24 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:19 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:17 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:16 ET
Veracyte published news for 2022 q2
SEC form 6
2022-08-09 17:16 ET
Veracyte published news for 2022 q2
SEC form 10
2022-08-03 08:01 ET
Veracyte reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
Veracyte reported for 2022 q2
SEC form 6
2022-08-02 16:15 ET
Veracyte published news for 2022 q2
SEC form 8
2022-08-02 00:00 ET
Veracyte reported for 2022 q2
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:12 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:11 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:06 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 20:04 ET
Veracyte published news for 2022 q1
SEC form 6
2022-06-16 16:15 ET
Veracyte published news for 2022 q1
SEC form 10
2022-05-04 00:00 ET
Veracyte reported for 2022 q1
SEC form 10
2022-05-03 17:57 ET
Veracyte reported for 2022 q1
SEC form 6
2022-05-03 16:12 ET
Veracyte published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Veracyte reported for 2022 q1
SEC form 6
2022-04-26 16:14 ET
Veracyte published news for 2022 q1
SEC form 6
2022-03-03 20:27 ET
Veracyte published news for 2021 q4
SEC form 10
2022-02-28 16:40 ET
Veracyte published news for 2021 q4
SEC form 6
2022-02-28 16:11 ET
Veracyte published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Veracyte published news for 2021 q4
SEC form 8
2022-02-28 00:00 ET
Veracyte published news for 2021 q4
SEC form 6
2022-02-22 16:40 ET
Veracyte published news for 2021 q4
SEC form 6
2022-01-13 16:47 ET
Veracyte published news for 2021 q4
SEC form 6
2022-01-11 16:50 ET
Veracyte published news for 2021 q4
SEC form 10
2021-11-09 16:37 ET
Veracyte published news for 2021 q3
SEC form 6
2021-11-09 16:11 ET
Veracyte published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Veracyte published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Veracyte published news for 2021 q3
SEC form 6
2021-08-04 16:14 ET
Veracyte published news for 2021 q2
SEC form 6
2021-08-03 08:09 ET
Veracyte published news for 2021 q2
SEC form 10
2021-07-29 16:19 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-29 16:16 ET
Veracyte published news for 2021 q2
SEC form 10
2021-07-29 00:00 ET
Veracyte published news for 2021 q2
SEC form 8
2021-07-29 00:00 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-20 16:44 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-16 09:02 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-13 16:58 ET
Veracyte published news for 2021 q2
SEC form 6
2021-07-12 08:37 ET
Veracyte published news for 2021 q2
SEC form 6
2021-06-10 16:21 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:20 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:18 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:16 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:12 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-10 16:11 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:40 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:38 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-08 16:35 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-03 17:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-06-01 07:16 ET
Veracyte published news for 2021 q1
SEC form 6
2021-05-19 17:16 ET
Veracyte published news for 2021 q1
SEC form 10
2021-05-10 16:23 ET
Veracyte published news for 2021 q1
SEC form 6
2021-05-10 16:17 ET
Veracyte published news for 2021 q1
SEC form 10
2021-05-10 00:00 ET
Veracyte published news for 2021 q1
SEC form 8
2021-05-10 00:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-23 16:12 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-15 16:55 ET
Veracyte published news for 2021 q1
SEC form 8
2021-04-15 00:00 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-05 16:58 ET
Veracyte published news for 2021 q1
SEC form 6
2021-04-05 16:50 ET
Veracyte published news for 2021 q1
SEC form 6
2021-03-23 16:38 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-22 09:21 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-15 16:23 ET
Veracyte published news for 2020 q4
SEC form 6
2021-03-03 16:07 ET
Veracyte published news for 2020 q4
SEC form 10
2021-02-22 16:18 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-17 16:17 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-05 06:17 ET
Veracyte published news for 2020 q4
SEC form 6
2021-02-03 08:21 ET
Veracyte published news for 2020 q4
SEC form 6
2021-01-25 08:33 ET
Veracyte published news for 2020 q4
SEC form 6
2020-12-16 17:14 ET
Veracyte published news for 2020 q3
SEC form 6
2020-11-17 16:39 ET
Veracyte published news for 2020 q3
SEC form 10
2020-11-02 16:20 ET
Veracyte published news for 2020 q3
SEC form 6
2020-11-02 16:15 ET
Veracyte published news for 2020 q3